MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
DVA stock logo

DVA

DaVita Inc.

$198.19
6.11
 (3.18%)
Exchange:  NYSE
Market Cap:  12.724B
Shares Outstanding:  54.417M
Delayed data
Calculate DVA Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Medical – Care Facilities
   
CEO:  Javier J. Rodriguez
Full Time Employees:  76000
Address: 
2000 16th Street
Denver
CO
80202
US
Website:  https://www.davita.com
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients’ homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita’s footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.

Click to read more…

Revenue Segmentation

MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2025/05/12 — Q1 quarter 2025

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue12,140,14712,815,55013,643,069
Gross Profit3,820,4304,217,0293,684,245
EBITDA2,321,0882,724,7222,642,097
Operating Income1,602,7842,090,4832,010,615
Net Income691,535936,342746,803

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets16,893,57817,285,26817,480,103
Total Liabilities14,150,22815,193,91716,321,664.999
Total Stockholders Equity1,056,097121,122-651,081.999
Total Debt11,116,42112,066,83615,049,989
Cash and Cash Equivalents380,063794,933757,747

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow2,059,0312,022,0381,886,500
Capital Expenditure-567,985-555,443-575,864
Free Cash Flow1,491,0461,466,5951,310,636
Net Income691,5351,250,7371,078,716
Net Change in Cash125,645415,191-122,078

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2029Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)15,629,222.006Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)16,338,099.781Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)15,893,400.700Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)3,089,474.072Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)3,229,600.017Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)3,141,695.048Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)1,561,454.463Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)1,653,991.180Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)1,595,940.328Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)1,824,651.665Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)1,907,410.424Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)1,855,493.513Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)18.120Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)18.770Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)17.720Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)2Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)1Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
12.816B  ?P/S
 (TTM)
: 
0.89
?Net Income
 (TTM)
: 
936.342M  ?P/E
 (TTM)
: 
16.57
?Enterprise Value
 (TTM)
: 
24.831B  ?EV/FCF
 (TTM)
: 
16.64
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
-1.33  ?ROIC
 (TTM)
: 
0.11
?Net Debt
 (TTM)
: 
11.136B  ?Debt/Equity
 (TTM)
: 
-17.5
?P/B
 (TTM)
: 
-17.14  ?Current Ratio
 (TTM)
: 
1.42

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
15.48Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MARKETSnap estimates DVA intrinsic value between $179.86 – $247.27 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about DVA valuation

Is DaVita Inc. (DVA) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for DaVita Inc. (DVA) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is DVA a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether DVA trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is DVA’s P/E ratio?

You can see DVA’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for DVA?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is DVA a good long-term investment?

Whether DVA fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

DVA

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

3.18
MARKETSnap

Trading Metrics:

Open: 193.63   Previous Close: 192.08
Day Low: 193.39   Day High: 198.27
Year Low: 101   Year High: 202.69
Price Avg 50: 171.47   Price Avg 200: 139.61
Volume: 634762   Average Volume: 878912

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Best Value Stocks to Buy for June 9th
09-06-2026 06:15
Best Value Stocks to Buy for June 9th
Best Growth Stocks to Buy for June 4th
04-06-2026 06:35
Best Growth Stocks to Buy for June 4th
DaVita Gains 21.4% in Three Months: How Should You Play the Stock?
03-06-2026 14:31
DaVita Gains 21.4% in Three Months: How Should You Play the Stock?
Best Growth Stocks to Buy for June 2nd
02-06-2026 06:21
Best Growth Stocks to Buy for June 2nd
Best Value Stocks to Buy for May 21st
21-05-2026 05:21
Best Value Stocks to Buy for May 21st
Best Growth Stocks to Buy for May 21st
21-05-2026 05:05
Best Growth Stocks to Buy for May 21st

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read